Skip to main content

News

Consensus Recommendations for Juvenile Dermatomyositis

SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) is a group established in 2012 to develop and optimize diagnostic and management regimens in Europe for children and young adults with rheumatic diseases.

No Added Lymphoma Risk with TNF Inhibitor Use

Warnings of cancer, especially lymphoma, have accompanied the development and promotion of tumor necrosis factor inhbitors (TNFi) in the treatment of RA and other inflammatory disorders.

Etanercept May Lower Alzheimers Risk in Rheumatoid Arthritis

The pathogenesis of Alzheimer's disease (AD) is unknown but some have speculated a role for inflammation.

EULAR: Guidance for Managing Lupus Pregnancy

The European League Against Rheumatism (EULAR) has published comprehensive recommendations on reproductive health and family planning for women with systemic lupus erythematosus and/or antiphospholipid syndrome – conditions that largely affect women of childbearing age.

Cryptochromes Regulate Circadian Inflammation

Circadian rhythms may be disrupted or become exaggerated in a variety of inflammatory conditions. For instance, interleukin-6 (IL-6) and IL-1 have a known circadian cycle to their production, but the same can not be said for TNF.

EULAR Updates Gout Guidelines

A EULAR task force of 24 individuals (including 15 rheumatologists) have updated their previous 2006 guidelines for gout. The current update, which includes 11 recommendations, is based on a systematic literature review and a Delphi consensus approach to recommendations.

RheumNow Week in Review – 5 August 2016

Highlights from this week on RheumNow.com include: 1. Having #RA in addition to solid cancer (breast, lung, prostate, colon) increases mortality rates by 40-50% in elders https://t.co/aitjusmOai 2. The global market for rheumatoid arthritis therapies was $19.9 billion in 2015, expected to reach $21.3B by 2020 https://t.co/d2Sh5C8y9f 3. Half of doctors never heard of MACRA:Medicare Access & CHIP Reauthorization Act. Starts on Jan 1st! https://t.co/eYgWBWCw6y Blog:https://t.co/sRKZSOFyNV And more!

Severe, Refractory Psoriasis in HIV-Positive Patients: Are TNF Inhibitors a Solution?

Psoriasis and psoriatic arthritis are more prevalent, often more severe, and sometimes refractory to conventional treatments in HIV-positive patients, but clinicians are understandably concerned about moving on to immunosuppressive anti-tumor necrosis factor (TNF) agents when other treatments fai

Serious Infections are Not Increased in HIV Patients Treated with TNF Inhibitors

Infections are a concern for many when using tumor necrosis factor-α inhibitor (TNFi) therapy to treat inflammatory disorders. Even moreso in those at higher risk.

Dinosaur Arthritis

The recent edition of Science has an interesting article on the cause of death in a dinosaur - septic arthritis.

Palentologists have unearthed a 70 million year old duck-billed dinosaur near New Jersey and found that the arm bones were not quite right.  

RAPID3: An Effective Assessment Tool in Spondyloarthritis

Serial biomarker or clinical metric assessments are ubiquitous and commonly used to assess patients with rheumatoid arthritis (HAQ, CDAI, RAPID3), lupus (C3, C4, dsDNA) and gout (uric acid). But numerous disorders are either harder to assess or have tools or metrics that that are not commonly used.

MRI Findings Match Patients' Experience With RA

Patient-reported outcomes in rheumatoid arthritis (RA) correlate independently with measures of inflammation and structural damage on MRI scans, according to data from a longitudinal study.

×